R&D | December 09, 2025
WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Subscribe To Our Newsletter & Stay Updated
